ReviewCNS drugs2015
Topiramate in Alcohol Use Disorders: Review and Update.
Review in CNS drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Treatments for internet addiction, sex addiction and compulsive buying: A meta-analysis.Journal of behavioral addictions · 2020Pooled it
- Pharmacological Treatments for Disordered Gambling: A Meta-analysis.Journal of gambling studies · 2019Pooled it
- Naltrexone Is Superior to Placebo for Abstinence and Craving Reduction in Alcohol-Associated Cirrhosis: NAL-CI Trial.Liver international : official journal of the International Association for the Study of the Liver · 2026Trial
- Neural cue reactivity and intrinsic functional connectivity in individuals with alcohol use disorder following treatment with topiramate or naltrexone.Psychopharmacology · 2025Trial
- Identifying responders to gabapentin for the treatment of alcohol use disorder: an exploratory machine learning approach.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025Trial
- A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder.The American journal on addictions · 2016Trial
- Topiramate effects on ethanol and sucrose binge-like intake, anxiety- and compulsive-like behavior in non-dependent male and female C57BL/6J mice.Psychopharmacology · 2026Article
- Off-label and investigational drugs in the treatment of gambling disorder: a critical review.Frontiers in pharmacology · 2026Review
- Psychological dimensions in alcohol use disorder: comparing active drinkers and abstinent patients.Frontiers in psychiatry · 2024Article
- The Effectiveness of Topiramate in the Treatment of Amphetamine and Methamphetamine Use Disorder: A Randomized Controlled Trial.Iranian journal of psychiatry · 2023Article
- Topiramate (Topamax): Evolving Role in Weight Reduction Management: A Narrative Review.Life (Basel, Switzerland) · 2023Review
- Evaluation of a Rapid Topiramate Titration Scheme for the Early Detection of Cognitive Side Effects.CNS drugs · 2022Article
- The Association of P300 Components With Clinical Characteristics and Efficacy of Pharmacotherapy in Alcohol Use Disorder.Frontiers in psychiatry · 2022Article
- Validation and Factor Analysis of the Obsessive Compulsive Drinking Scale (OCDS) in the Chinese Population.Frontiers in psychiatry · 2021Article
- Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis.Drug and alcohol dependence · 2020Article
- Pharmacotherapies and personalized medicine for alcohol use disorder: a review.Pharmacogenomics · 2020Review
- A Novel Sulfonamide, 4-FS, Reduces Ethanol Drinking and Physical Withdrawal Associated With Ethanol Dependence.International journal of molecular sciences · 2020Article
- Pharmacogenetics of alcohol addiction: current perspectives.The application of clinical genetics · 2019Article
- An Overview of Pharmacotherapy Options for Alcohol Use Disorder.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2018Article
- From gene networks to drugs: systems pharmacology approaches for AUD.Psychopharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, a limited number of pharmacological agents exist to treat alcohol use disorders (AUDs), and there is growing interest in new therapeutic tools. In this framework, topiramate may represent a useful treatment option, although its use is not yet approved for AUDs. The main focus of this review is to discuss all the existing data supporting the use of topiramate in AUDs, with an emphasis on the most recent and relevant clinical implications. In addition, the profile of the alcoholic patient who may benefit more from the use of topiramate is outlined. In this regard, the authors conducted a PubMed search of clinical human studies published in English using the following key words: topiramate alcohol dependence, topiramate alcohol withdrawal and topiramate alcoholism. The evidence suggests that topiramate could be an effective treatment option for the management of AUDs, while there are limited results for its use to treat alcohol withdrawal syndrome. In particular, topiramate shows a greater beneficial effect in subjects with a typology of craving characterised by drinking obsessions and automaticity of drinking. Topiramate, within the dosage range of 75-300 mg/day, could be considered as a first-line treatment option for the management of AUDs. Its use appears to be safe and well-tolerated, especially in light of very recent findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.